OptiNose, Inc. (OPTN)

NASDAQ: OPTN · IEX Real-Time Price · USD
2.19 -0.01 (-0.45%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap180.02M
Revenue (ttm)68.49M
Net Income (ttm)-90.54M
Shares Out82.20M
EPS (ttm)-1.71
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume407,439
Open2.16
Previous Close2.20
Day's Range2.11 - 2.27
52-Week Range1.46 - 4.85
Beta0.93
AnalystsStrong Buy
Price Target9.20 (+320.1%)
Earnings Daten/a

About OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase 3b clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also d...

IndustryPharmaceuticals
IPO DateOct 13, 2017
CEOPeter Miller
Employees204
Stock ExchangeNASDAQ
Ticker SymbolOPTN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for OptiNose stock is "Strong Buy." The 12-month stock price forecast is 9.20, which is an increase of 320.09% from the latest price.

Price Target
$9.20
(320.09% upside)
Analyst Consensus: Strong Buy

News

Rising P/E: An Overlooked Trick to Land on 5 Winning Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other symbols:LAZYMPAAQTNTSTKL
1 month ago - Zacks Investment Research

Optinose Announces Appointment of Two New Members to Board of Directors

YARDLEY, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Bo...

1 month ago - GlobeNewsWire

Optinose to Present at the Piper Sandler Virtual Healthcare Conference

YARDLEY, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that C...

2 months ago - GlobeNewsWire

OptiNose (OPTN) Sees Hammer Chart Pattern: Time to Buy?

OptiNose (OPTN) has been struggling lately, but the selling pressure may be coming to an end soon.

2 months ago - Zacks Investment Research

After Plunging 44.2% in 4 Weeks, Here's Why the Trend Might Reverse for OptiNose (OPTN)

The heavy selling pressure might have exhausted for OptiNose (OPTN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in ...

2 months ago - Zacks Investment Research

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

YARDLEY, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced ...

2 months ago - GlobeNewsWire

Optinose Announces Closing of $46.0 Million Public Offering of Common Stock

YARDLEY, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cl...

2 months ago - GlobeNewsWire

Optinose Announces Pricing of Public Offering of Common Stock

YARDLEY, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pr...

2 months ago - GlobeNewsWire

See Why Optinose Shares Plunged To 52-Week Low Today

ENT and allergy-focused company Optinose Inc (NASDAQ: OPTN) posted Q3 Xhance (fluticasone propionate) sales of $21.8 million, +41% Y/Y, missing the consensus of $23.48 million. The Company held cash and...

2 months ago - Benzinga

OptiNose (OPTN) Reports Q3 Loss, Lags Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of 13.51% and -8.68%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Optinose Announces Proposed Public Offering of Common Stock

YARDLEY, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that i...

2 months ago - GlobeNewsWire

Optinose Reports Third Quarter 2021 Financial Results and Recent Operational Highlights

Third quarter 2021 XHANCE net revenue of $22 million increased 41% compared to third quarter 2020

2 months ago - GlobeNewsWire

Optinose Announces Reporting Date for Third Quarter 2021 Financial Results

Conference Call and Webcast to be held November 16, 2021 at 8:30 a.m. Eastern Time

2 months ago - GlobeNewsWire

Will OptiNose (OPTN) Report Negative Q3 Earnings? What You Should Know

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Optinose Completes Patient Recruitment in Second Pivotal Trial for XHANCE in Chronic Sinusitis

Company Expects Top-Line Results in Second Quarter 2022

2 months ago - GlobeNewsWire

Optinose to Present at the Cantor Virtual Global Healthcare Conference

YARDLEY, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that ...

4 months ago - GlobeNewsWire

OptiNose (OPTN) Reports Q2 Loss, Tops Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of -2.33% and 5.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

OptiNose: Q2 Earnings Insights

Shares of OptiNose (NASDAQ:OPTN) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were up 21.43% year over year to ($0.44), which missed the estimate of ($...

5 months ago - Benzinga

Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights

Second quarter 2021 XHANCE net revenue of $18.4 million increased 79% compared to second quarter 2020

5 months ago - GlobeNewsWire

Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis

Company Expects Top-Line Results in First Quarter 2022

5 months ago - GlobeNewsWire

OptiNose (OPTN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Optinose Technology Inventor Per Djupesland Named Winner of European Inventor Award 2021 for Industry

Co-founder and Chief Scientific Officer of Optinose AS honored for his invention of the technology used in the Optinose Exhalation Delivery System Co-founder and Chief Scientific Officer of Optinose AS ...

6 months ago - GlobeNewsWire

Experts Issue New Treatment Algorithm for Chronic Rhinosinusitis with Nasal Polyps That Highlights Role of XHANCE® In...

YARDLEY, Pa., June 2, 2021 /PRNewswire/ -- Optinose (NASDAQ:OPTN), a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy ...

7 months ago - PRNewsWire

Optinose to Present at the Jefferies Virtual Healthcare Conference

YARDLEY, Pa., June 01, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that C...

7 months ago - GlobeNewsWire

OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

OptiNose (OPTN) delivered earnings and revenue surprises of 5.77% and 4.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research